TP53 and B-cell chronic lymphocytic leukemia: Thus, the German CLL Study Group has sequenced samples from a large cohort of 1,124 newly diagnosed patients to ascertain the impact of SF3B1 mutations on prognostic markers [63], whereas the CLL8 trial was interrogated for TP53, NOTCH1 and SF3B1 mutations and their relationship with treatment outcome [64].